Administration of the USA on sanitary inspection behind quality of foodstuff and medicines (FDA) on 15 June withdrew permission for the use of chloroquine and hydroxychloroquine for the treatment of patients with COVID-19. About it it is spoken in the statement of the FDA.
“The FDA has determined that chloroquine and hydroxychloroquine are unlikely to be effective for the treatment COVID-19. In addition, in light of the serious side effect for the heart and other potential serious side effects potential benefits of of chloroquine and hydroxychloroquine no longer outweigh the known and potential risks of its use”, – stated in the message.
The FDA stressed that it is a necessary condition for granting the permit.
In February and March 2020, about “apparent effectiveness” of chloroquine in the treatment of coronavirus infection, said the Chinese physicians, in April French, pointing out a large number of unwanted side effects.
In may of the admission of hydroxychloroquine as a preventive measure against coronavirus was declared by the President of the United States Donald trump. Later, he promised to stop taking the drug.
At the end of may in the prestigious medical journal the Lancet published a Preprint of a study in which it was alleged that these drugs substantially increase the risk of death in patients with COVID-19 (later, the authors withdrew the study because of questions about the reliability of the analyzed data).
After the publication of the study by the world health organization has suspended trials of hydroxychloroquine. June 3, testing was resumed. “Based on available data about mortality of the members of the Committee for security and monitoring data concluded that there is no reason to change the treatment Protocol. The Executive team had received the recommendation and approved the continuation of all clinical trials, including hydroxychloroquine,” – said the Director General of the who tedros adhanom Ghebreyesus.